Explore

Cancer Research and Therapy 2018

Global Conference on Cancer Research & Therapy 2018

venice, Italy
6 - 7 September 2018
The conference ended on 07 September 2018

Important Dates

Abstract Submission Deadline
15th November 2017
Early Bird Deadline
5th February 2018
Abstract Acceptance Notification
15th August 2018
Final Abstract / Full Paper Deadline
20th August 2018

About Cancer Research and Therapy 2018

Genoteq welcomes you to attend the Global Conference on Cancer Research & Therapy (GCCRT- 2018) during September 07-09, 2017 Rome, Italy. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cancer research. Cancer therapy 2018 anticipates more than 200 participants around the globe with thought provoking Keynote lectures, Oral and Poster presentations. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. For more details regarding the conference please contact cancer@genoteqhealthcare.com

Topics

Cancer, Cancer research, Cancer treatments, Hemato-oncology and blood cancers, Cancer therapy, Cancer conferences 2018, Cancer events, Cancer conferences, International conferences

Call for Papers

  1. Diagnosis and therapy of cancer
  2. Epidemiology and prevention
  3. Healthcare delivery Public policy issues
  4.  ethics and confidentiality
  5. Living with and beyond cancer: physical, psychological and social impacts and their management
  6. Research into care at the end of life
  7. Cancer cell and model system
  8. Molecular and cellular mechanisms of oncogenesis and tumor suppression
  9. Breast Cancer research
  10. Clinical oncology
  11. Recent advances in drug discovery and therapy

 

Useful Links         

 Abstract Submission: 

http://www.cancer-conferences....

Registration :    

http://www.cancer-conferences....

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.